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Pathology, Coombe Women’s and Infants University Hospital, Dublin, IrelandA B S T R A C TObjectives: To systematically review the choice of comparator strat-
egies in cost-effectiveness analyses (CEAs) of human papillomavirus
testing in cervical screening. Methods: The PubMed, Web of Knowl-
edge, and Scopus databases were searched to identify eligible model-
based CEAs of cervical screening programs using human papilloma-
virus testing. The eligible CEAs were reviewed to investigate what
screening strategies were chosen for analysis and how this choice
might have inﬂuenced estimates of the incremental cost-
effectiveness ratio (ICER). Selected examples from the reviewed
studies are presented to illustrate how the omission of relevant
comparators might inﬂuence estimates of screening cost-
effectiveness. Results: The search identiﬁed 30 eligible CEAs. The
omission of relevant comparator strategies appears likely in 21
studies. The ICER estimates in these cases are probably lower than
would be estimated had more comparators been included. Five of the
30 studies restricted relevant comparator strategies to sensitivityee front matter Copyright & 2015, International S
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.1016/j.jval.2015.09.2939
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ndence to: James O’Mahony, Department of Healthanalyses or other subanalyses not part of the principal base-case
analysis. Such exclusion of relevant strategies from the base-case
analysis can result in cost-ineffective strategies being identiﬁed as
cost-effective. Conclusions: Many of the CEAs reviewed appear to
include insufﬁcient comparator strategies. In particular, they omit strat-
egies with relatively long screening intervals. Omitting relevant compara-
tors matters particularly if it leads to the underestimation of ICERs for
strategies around the cost-effectiveness threshold because these strategies
are themost policy relevant from the CEA perspective. Consequently, such
CEAs may not be providing the best possible policy guidance and lead to
the mistaken adoption of cost-ineffective screening strategies.
Keywords: cervical screening, comparator choice, cost-effectiveness
analysis, model speciﬁcation.
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This review considers the choice of screening strategies com-
pared in cost-effectiveness analyses (CEAs) of cancer screening
programs. It investigates how the choice of which strategies are
compared can inﬂuence cost-effectiveness estimates and result-
ing policy advice. Speciﬁcally, this review addresses the choice of
comparator strategies against which the cost-effectiveness of a
given screening strategy is estimated. This issue is considered in
the particular context of CEAs of cervical cancer screening using
testing for the human papillomavirus (HPV).
The primary measure of cost-effectiveness is the incremental
cost-effectiveness ratio (ICER), which is the ratio of additional
costs to additional health effects of an intervention relative to its
next best alternative (once strategies subject to simple and
extended dominance have been eliminated) [1,2]. Because theICER is an incremental measure, it depends not only on the costs
and effects of the strategy for which it is estimated but also on
those of the comparator strategy.
Typically, decision makers use ICERs in conjunction with a cost-
effectiveness threshold, which indicates the maximum willingness
to pay for an additional (quality-adjusted) life-year [3]. The strategy
with the highest ICER within the threshold is optimal from the
cost-effectiveness perspective because it is the most effective
intervention that does not exceed the willingness-to-pay limit.
More broadly, those strategies with ICERs closest to the threshold
are deﬁned here as the CEA-relevant strategies because they yield
more net health beneﬁt than do strategies with ICERs far above or
below the threshold. It is the adequacy of the choice of comparators
for these CEA-relevant strategies that is the focus of this review.
A particular characteristic of screening especially relevant to
CEA modeling is that it can often be applied at a wide range ofociety for Pharmacoeconomics and Outcomes Research (ISPOR).
Policy and Management, Trinity College Dublin, 2-4 Foster Place,
Table 1 – The PubMed version of the search string.
Cervi*[tiab] OR pap[tiab] OR cytolog*[tiab] OR (cervi*[tiab] AND
cancer[tiab])
AND (HPV[tiab] OR “Human Papillomavirus”[tiab])
AND (screen*[tiab] OR prevent*[tiab])
AND (cost-effect*[tiab] OR “cost effect*”[tiab] OR CEA[tiab] OR CUA
[tiab] OR HTA[tiab]OR “health technology assessment”[tiab] OR
“health economic”[tiab])
AND English[lang]
AND (“1995/01/01”[PDAT] : “2013/10/01”[PDAT])
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 1 3 8 – 1 1 5 1 1139intensities, depending on the screening interval, screening age
range, type of tests used, and the diagnostic criteria for follow-up.
As a result, CEAs considering a wide range of screening inten-
sities can yield a wide range of ICERs, varying from those well
below the threshold through to those around the threshold and
then on to well above the threshold.
What is already well appreciated in CEA theory is the impor-
tance of including relevant comparators for the reliable estima-
tion of ICERs. Indeed, the Washington Panel on Cost-
Effectiveness in Health and Medicine uses a cancer screening
example to illustrate the importance of including relevant com-
parators [4]. It notes that to correctly estimate the ICER of annual
screening, it must be compared with biennial screening rather
than with no screening. The general principle is that to appraise
the cost-effectiveness of a given screening strategy, the next best
strategy should be included as a comparator against which to
estimate the ICER. If less intense comparators are omitted, then
the estimated ICER is likely to be lower than that in a more
complete comparison, thereby giving an unrepresentatively
favorable impression of the strategy’s cost-effectiveness.
The motivation for this review was an observation that
although most models used in CEAs of HPV screening are care-
fully constructed and well described, many include relatively few
comparator screening strategies. Consequently, they may fail to
adequately estimate the cost-effectiveness of certain strategies.
This, in turn, could lead decision makers to mistakenly adopt
cost-ineffective policies, thereby wasting health care resources.
Therefore, the aim of this study was to systematically assess the
adequacy of the choice of comparator strategies in CEAs of HPV
testing in cervical screening. It seeks to demonstrate the impor-
tance of appropriately chosen comparators for the reliable esti-
mation of ICERs. Although the review addresses the speciﬁc case
of cervical screening, it is hoped that the example will illustrate
the importance of including relevant comparators in CEAs in
general to both analysts and decision makers alike.Fig. 1 – Composition of literature search and exclusions.
CEA, cost-effectiveness analysis.The Example of Cervical Screening
Cervical screening has proved highly successful in reducing
cancer incidence and mortality [5]. Cervical screening is widely
practiced in developed countries, either through organized pro-
grams or on an ad-hoc basis [6,7]. There is a wide variety of
possible screening strategies because alternative screening inter-
vals and start and stop ages can be used. Similarly, screening
may use different tests, such as conventional Papanicolaou
cytology or the more recent alternative of liquid-based cytology.
Furthermore, there are alternative combinations of primary
screening tests and triage testing for inconclusive primary screen
results and alternative classiﬁcations of borderline results. In
practice, there are large variations between countries in screen-
ing recommendations. For example, the German recommenda-
tions are for annual screening from age 20 years, whereas the
Dutch screening program has used screening every 5 years from
age 30 years [8,9].
The range of possible strategies continues to expand, in part
because of the recent advent of HPV DNA testing. HPV testing
offers better sensitivity for the detection of high-grade lesions,
but at the cost of lower speciﬁcity [10–12]. HPV testing is typically
used in conjunction with cytology, for example, using HPV and
cytology as the primary test and the triage test, respectively.
Some proposed strategies also involve a switch in the order the
tests are used [8], using cytology as the primary test and HPV as
the triage test, in younger women in whom transient HPV
infections are more prevalent. Importantly, for this review, HPV
testing has been recognized as offering the potential for longer
screening because a negative HPV test result is associated with alonger period of reduced risk of precancerous lesions than is
negative cytology [13].
Another relevant development is the HPV vaccine, which has
been implemented in many countries recently. Although current
vaccines are expected to reduce the incidence of cervical cancer,
the level of protection is not anticipated to be sufﬁcient to
abandon screening [14]. Reduced incidence will reduce the cost-
effectiveness of current screening services, so screening intervals
may need to lengthen for screening to be cost-effective [15].Methods
The PubMed, Web of Knowledge, and Scopus databases were
searched for model-based CEAs of cervical screening using HPV
testing. The search string from the PubMed search is given in
Table 1. Figure 1 shows the search protocol. The search was
restricted to English language academic articles published
between January 1995 and September 2013. The search excluded
conference proceedings, government reports, and gray literature.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 1 3 8 – 1 1 5 11140The search returned 382, 438, and 361 titles from PubMed, Web of
Knowledge, and Scopus, respectively. Combining and removing
duplicates gave 646 unique studies, the titles and abstracts of
which were then reviewed by one reviewer (J.F.O’M.).
Studies were excluded if they did not relate to cervical cancer
or cervical screening. Studies were included only if they con-
cerned screening in countries classiﬁed as advanced economies
by the International Monetary Fund [16]. These studies were
excluded for the two reasons that the screening services in such
countries are very different from those in developed settings and
it is markedly less clear what the appropriate cost-effectiveness
thresholds are. Studies were excluded if they were trial-based
CEAs because the intermediary outcome measures such as cases
detected are not directly comparable with estimates of life-years
gained (LYG) or quality-adjusted life-years (QALYs) from model-
based CEAs [17–21]. Methodological studies and reviews were also
excluded [22–25].
The remaining studies were reviewed independently in detail
by two reviewers (J.F.O’M. and S.K.N.). Discordance between
reviewers regarding the inclusion of articles was resolved by
reviewing the studies together. One analysis was published in
two similar articles, one in an academic journal [26], the other in
a government journal [27]; the latter was excluded. In addition,
the article by van Ballegooijen et al. [28] was excluded because it
is primarily an exploratory analysis of two alternative hypotheses
regarding disease progression rather than a standard CEA.
Another study was excluded because it did not report costs and
effects estimates or a cost-effectiveness plane, but reported only
ICERs, meaning that it was not possible to appraise the appro-
priateness of the comparisons made [29]. The reference lists of
the included studies were reviewed, and this yielded an addi-
tional article [30]. The ﬁnal number of CEAs reviewed was 30
[8,14,15,26,30–55].
The reported costs and effects estimates from the 30 studies
were extracted by the two reviewers and compiled for analysis.
The cost-effectiveness planes and ICERs were reproduced from
the available results. Some studies reported ICERs that are at
variance with the conventional interpretation as the ratio of
incremental costs to incremental health effects relative to the
next most effective strategy [38,52,54,55]. In these cases, the
ICERs were recalculated from the reported costs and effects.
The reproduced cost-effectiveness planes were used to review
the comparisons and interpretations made by the studies.
The selected studies were reviewed to assess the adequacy of
the comparators included. This was informed by a previous CEA of
cervical screening that assessed conventional cytology over a
broad range of screening ages and intervals [56]. It estimated an
efﬁcient frontier without pronounced kinks, as the ICERs increased
steadily from long intervals and short screening age ranges (low-
intensity strategies) through to very high ICERs for short screening
intervals and long screening ages ranges (high-intensity strat-
egies). It was assumed that if the reviewed studies also simulated
a broad range of screening intensities they would ﬁnd similarly
shaped frontiers, in which low-intensity strategies would be the
comparators against which the ICERs of higher-intensity strategies
were estimated. This assumption implies that if low-intensity
comparators have been omitted from the analysis, then some of
the resulting ICERs are likely to have been underestimated.
The primary objective was to assess the adequacy of the
comparator against which the ICER of the optimal strategy was
estimated in each study. The cost-effectiveness threshold used to
identify the optimal strategy was retrieved from each study, or, if
not explicitly stated, from another included study for the same
country. In one case this was not possible [26], so the gross
domestic product per capita threshold suggested by the World
Health Organization from the year of publication was used
instead [57,58].The primary criterion used to identify the omission of a
relevant comparator was the failure to include a screening
interval longer than that found for the optimal strategy. Studies
without such a longer interval strategy were considered likely to
have omitted relevant comparators. The analysis also considered
the ratio of the ICER of the optimal intervention relative to the
next higher ICER on the efﬁcient frontier. Larger ratios were
considered more suggestive of the omission of relevant compa-
rators. Finally, the analysis also considered other aspects of the
strategies compared, including the screening age ranges, the
alternative screening technologies, and the range of primary
screening and triage protocols simulated.
This review is based on the assumption that all possible
strategies are potential comparators. Some CEAs, however, may
be conducted with a speciﬁc research objective that (implicitly or
explicitly) precludes some comparators. For example, the objec-
tive of Vijayaraghavan et al. [54] to assess the cost-effectiveness
of adding HPV triage testing to current screening services in the
United States may preclude alternative screening intervals.
Despite this, the criteria described above were applied to all
studies irrespective of the stated research objectives.
Some studies assessed more than one population; simulating
either vaccinated and unvaccinated women or a number of
countries or provinces. In such cases, the issue of comparator
omission was sometimes apparent in some but not all popula-
tions. This analysis reports results for subgroups in which the
issue of comparator omission is suspected.
The results are further illustrated by considering cost-
effectiveness planes for four examples from the review. In three
of these examples, additional points marking hypothetical costs
and effects estimates for longer screening intervals show how the
efﬁcient frontier might change if additional comparators were
included. The positions of these hypothetical comparators are
informed by inference from other studies and the assumption of
decreasing marginal returns in terms of costs and effects as the
screening interval is shortened.Results
First, an overview of the studies included in this review is
presented, summarizing the simulated populations and strat-
egies. The principal results of this review are then shown,
detailing which studies have likely omitted relevant comparators.
These results are then complemented with several speciﬁc
examples to illustrate the issues in greater detail.
Overview of Eligible CEAs
Details of the eligible studies are presented in Table 2. The 30
CEAs were published between 2002 and 2013. The most frequent
countries of origin were the United States and The Netherlands
with eight studies each, followed by Canada with ﬁve.
The number of alternative screening strategies compared
varies widely, ranging from 4 to more than 1500. Four studies
considered more than 100 strategies [8,14,42,46], and 21 studies
considered fewer than 20 strategies [15,18,26,30–33,35,36,38,
39,41,43,45,48–50,52–55].
The intensity of screening varied widely. Of the 30 CEAs
reviewed, all but 2 varied the screening interval [48,50]. Fourteen
studies considered only two or three alternative screening inter-
vals [18,30–32,34,35,38–40,45,49,53–55]. Furthermore, only eight
studies considered intervals longer than 5 years, all of which
were in European settings [8,15,33,36,37,41,46,52]. Similarly, only
10 varied the screening age range [8,14,15,26,30,41,42,46,47,52].
Some considered only small changes to the screening age range,
whereas others considered much broader ranges of alternative
Table 2 – Summary of key attributes and strategies compared in reviewed studies.
Study Country No. of
strategies
modeled
Screening
intervals
simulated
(y)
Screening age ranges (y) Screening
switch
ages (y)*
Vaccinated
population
Choice of
modeled
strategies
justiﬁed
Start Stop
age age
Accetta et al. [31] Italy 18 3, 5 25 65 – Yes No
Balasubramanian et al. [32] United States 15 1, 2, 3 18 85 – No No
Berkhof et al. [34] The Netherlands 20 3 (5 in SA) 30 60 – No No
Berkhof et al. [33] The Netherlands 13 5, 6, 7.5, 10 30 60 – No No
Bidus et al. [35] United States 10 1, 2, 3 18 85 30 No No
Bistoletti et al. [36] Sweden 4 3, 4, 5, 9 32 60 – No No
Burger et al. [37] Norway 98 3, 4, 5, 6 25 70 31, 34 Yes Yes
Chen et al. [38] Taiwan 5 1, 3, 5 30 70 – Yes No
Chow et al. [39] Taiwan 10 1, 3, 5 30 69 – No No
Chuck [40] Canada 21 1, 2, 3 18 69 30 No No
Coupé et al. [41] The Netherlands 10 5, 6, 7.5, 10 30–35 60 – Yes No
Coupé et al. [15] The Netherlands 10 5, 6, 7.5, 10 30 60 – Yes No
Diaz et al. [14] Spain 333† 1, 2, 3, 4, 5 18, 25, 30 50, 65, 85 35, 40 Yes No
Goldhaber-Fiebert et al. [42] United States 186 1, 2, 3, 5 18, 21, 25 NS 25, 30, 35 Yes No
Goldie et al. [43] United States 17 1, 2, 3, 4 18 NS 30 No No
Kim et al. [44] United States 57 1, 2, 3, 5 18 NS – No No
Kim et al. [45] United Kingdom, The Netherlands,
France, Italy
6–8 3, 5 25, 30 60, 65 30 No No
de Kok et al. [46] The Netherlands 1539 3, 4, 5, 6, 7,
8, 9, 10
25, 27,
30, 32
31–70 – Yes No
Kulasingam et al. [47] Canada 27 1, 2, 3, 5 18, 25 70 – No No
Legood et al. [48] United Kingdom 5 3–5 25 64 35 No No
Mandelblatt et al. [30] United States 19 2, 3 20 65, 75, lifetime – No Yes
Maxwell et al. [49] United States 10 1, 2, 3 18 85 – No No
Mittendorf et al. [50] Germany 4 10 (5 in SA) 20 – – No No
Östensson et al. [51] Sweden 8 2, 3, 3–5, 5 23 60 (65 in SA) 35 No No
Rogoza et al. [52] Canada, United States, The Netherlands,
United Kingdom, Taiwan
4–6 1, 3, 5, 7 15, 18,
20, 25, 30
52, 58, 60, 68–70, 85,
87, 89, 99, 100
– Yes No
van Rosmalen et al. [8] The Netherlands 1539 3, 4, 5, 6,
7, 8, 9, 10
25, 27,
30,32
31–70 33 No No
Sherlaw-Johnson and
Philips [53]
United Kingdom 15 3, 5 21 64 30 No No
Sroczynski et al. [26] Germany 18 1, 2, 3, 5 20–25 in
SA
Lifetime 30 No No
Vijayaraghavan et al. [55] Canada 8 1, 3 30 NS – No No
Vijayaraghavan et al. [54] Canada 7 2, 3 30 NS – No No
HPV, human papillomavirus; NS, not stated; SA, sensitivity analysis.
* The screening switch age is the age at which HPV testing is used at the primary screen test and cytology as the triage test, with the converse order being used in younger women.
† Personal communication.
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 1 3 8 – 1 1 5 11142start and stop ages. Among the studies with ﬁxed screening age
range, start ages between 18 and 30 years were typical, as were
stop ages between 60 and 70 years.
Primary HPV screening was considered by all but four studies
[34,44,48,52]. Alternative triage strategies for borderline primary
cytology or positive primary HPV test results were considered by
19 studies [8,14,31,32,34,35,40–48,52–55]. Strategies featuring a
switch from primary cytology screening with HPV triage to
primary HPV with cytology triage partway through the screening
program were considered by 12 studies [8,14,18,26,35,37,40,
42,43,45,48,53].
The review also recorded which studies explained the
rationale for the range of strategies compared, in particular the
screening interval and the screening age range. Only two pro-
vided explicit justiﬁcations for the intervals considered [30,37].
Both explained that the intervals compared were those of
policy recommendations, although neither included any addi-
tional comparators with longer intervals to serve as comparators
to the recommended strategies. Although the remaining
studies did not explain the choice of strategies, many mentioned
current guidelines, the status quo strategy, or the possibility
of lengthening screening intervals with HPV testing when
describing what strategies were compared [8,14,15,26,31,
33–36,38–41,45–55].
Evidence of Omission of Relevant Comparators
Table 3 presents the principal results of the review. It records the
threshold and the associated optimal strategy including the
optimal interval. Relevant comparators have likely been omitted
in 21 of the 30 studies reviewed. These are recorded in the table
as having “probably” omitting relevant comparators. In most
cases, this conclusion is based on the observation that a longer
screening interval than that found to be optimal was not
included.
There are three exceptions to the general observation that
studies without longer intervals have omitted relevant compara-
tors. Although Rogoza et al. [52] does include longer intervals, the
choice of screening age ranges is inconsistent between the
alternative intervals simulated. In particular, the annual interval
found to be optimal has a relatively short screening age range of
25 to 60 years, whereas the triennial comparator modeled has an
age range of 15 to 87 years. The inclusion of a triennial strategy
with an age range closer to 25 to 60 years would probably be
relevant, as would a biennial comparator. Similarly, the choice of
screening protocols is inconsistent between the intervals consid-
ered in Chen et al. [38] because combined cytology and HPV
testing is not simulated in all intervals considered. Furthermore,
although annual cytology is found cost-effective relative to
triennial cytology, no biennial strategy is modeled; despite this,
biennial screening is typically found to be a relevant comparator
to annual screening in other studies. Finally, although Goldhaber-
Fiebert et al. [42] do not include intervals longer than that
identiﬁed as optimal for vaccinated women, the strategies found
to be efﬁcient at shorter intervals suggest that the broad range of
screening age ranges and screening protocols simulated probably
provide sufﬁcient comparators to correctly estimate the ICER of
the optimal strategy.
The likely omission of relevant comparators is quite distinct
in some cases, such as Accetta et al. [31] and Bidus et al. [35].
This is evidenced in part by a high ratio of the next efﬁcient
ICER to that of the optimal strategy. There are other cases in
which the omission of comparators is much less certain. For
example, although Burger et al. [37], Kim et al. [45], and
Sherlaw-Johnson and Philips [53] all omit intervals longer than
that found to be optimal, the ratio of adjacent ICERs in these
cases is much lower and it is less certain whether the ICER ofthe optimal interval would change with the inclusion of addi-
tional comparators.
Illustrative Examples of Omissions
Four examples are now presented to further illustrate the
omission of relevant comparators. The ﬁrst is one of the distinct
examples of comparator omission provided by Accetta et al. [31].
It assessed four combinations of primary and triage testing at
screening intervals of 3 and 5 years. Note that although the
original analysis considered unvaccinated and vaccinated
women together, we consider them separately. Figure 2A shows
the estimates for unvaccinated women. There is a notably
sharp kink in the frontier around the second efﬁcient strategy
as the ICER increases from €5,700/QALY to €68,400/QALY.
This corresponds to the highest ratio of adjacent ICERs observed
in this review of 11.8. Similarly kinked frontiers are also found
in other analyses with few alternative intervals [32,49,53].
Such kinked frontiers contrast with the gently curved frontiers
found in analyses with a broader range of screening strategies
[8,42].
It is possible to anticipate how the frontier from Accetta
et al. [31] might appear if additional strategies with longer
intervals of 6, 7, and 8 years were modeled. Figure 2B includes
three markers showing hypothetical costs and effects esti-
mates for such intervals. The frontier over these supposed
points is marked with the dotted line. In such a case, the
frontier would not be sharply kinked, but be more gently
curved. Furthermore, it can reasonably be assumed that the
ICER estimate of €5700/QALY for the 5-year interval would be
revised upward, meaning that the reported ICER is probably an
underestimate.
The lack of sufﬁcient comparators in Accetta et al. [31] is
easily identiﬁed from the noticeably kinked frontier. The same
problem of insufﬁcient comparators, however, can also be found
in studies considering a broader range of strategies without
obviously kinked frontiers. For example, Goldie et al. [43] con-
siders four combinations of primary and triage testing at
intervals of 1, 2, 3, and 4 years. The corresponding cost-
effectiveness plane in Figure 3 has been rescaled for clarity,
and the points representing no screening and the four annual
screening strategies are not shown. Although the frontier
appears gently curved, the ﬁgure shows that it is certainly
possible that a 5-year interval strategy could lie to the southwest
of the 4-year interval strategy, which has an ICER of $20,600/
QALY. If a 5-year interval strategy lay at the point marked with
the pentagon, this would result in a higher ICER than $20,600/
QALY for the 4-year interval strategy.
The omission of 5-year interval comparators in Goldie et al.
[43] is particularly relevant because the omitted strategies would
likely form the most CEA-relevant part of the efﬁcient frontier. As
Goldie et al. [43] note, although there is no established threshold
in the United States, a value of $50,000/QALY is commonly used.
The strategies with ICERs of $95,300/QALY and above are not
CEA-relevant because they exceed the threshold, whereas the
$20,600/QALY strategy is optimal. Therefore, it is signiﬁcant that
the inclusion of a 5-year interval comparator would probably
inﬂate this strategy’s ICER.
It is not possible to know how much greater the ICER of a 4-
year interval strategy would be if a 5-year interval was included.
Had 4-year screening intervals been omitted, however, the ICER
of the efﬁcient 3-yearly strategy would be $23,500/QALY rather
than $95,300/QALY. This large difference indicates how impor-
tant the omission of comparators can be.
The importance of the CEA-relevant portion of the frontier is
further illustrated by contrasting Goldie et al. [43] with an example
in which additional comparators would change the frontier, but
Table 3 – Assessment of reviewed studies for omission of relevant comparator strategies.
Study Subgroup
considered
Threshold
stated
explicitly
Threshold Optimal
strategy
Comparator Interval
longer
than
optimal
interval
simulated
Optimal
strategy
ICER
Next
efﬁcient
strategy
ICER
ICER ratio
between
optimal
and next
efﬁcient
strategy
Relevant
comparators
omitted
Accetta et al. [31] Unvaccinated Yes €50,000/
QALY
HPV with
cytology triage
every 5 y
Cytology with
HPV triage
every 5 y
No €5,800/
QALY
€68,400/
QALY
11.8 Probably
Balasubramanian
et al. [32]
– No $50,000/
QALY
HPV with
cytology triage
every 3 y
No screening No $9,900/
QALY
$70,200/
QALY
7.1 Probably
Berkhof et al. [34] – No €20,000/
QALY
Cytology with
combined
triage of
cytology and
HPV at 6 mo,
every 5 y
Cytology with
HPV triage
followed by
combined
cytology and
HPV testing at
6 and 18 mo,
every 5 y
No €8,700/
QALY
€22,000/
QALY
2.5 Probably
Berkhof et al. [33] – Yes €20,000/
QALY
HPV with
cytology triage
every 5 y
HPV with
cytology triage
every 6 y
Yes €18,800/
QALY
€67,100/
QALY
3.6 Probably not
Bidus et al. [35] – Yes $50,000/
LYG
Cytology with
HPV triage
every 3 y
No screening No $5,100/ LYG $56,700/
LYG
11.1 Probably
Bistoletti et al. [36] – No NA* Combined
cytology and
HPV testing
every 9 y
NA* No Cost saving NA – Probably
Burger et al. (2012)
[37]
Vaccinated Yes $83,000/
LYG
HPV with
cytology triage
every 6 y
No screening,
vaccination
only
No $80,000/
LYG
$92,000/
LYG
1.2 Probably not
Chen et al. [38] – Yes $40,000/
LYG
Cytology alone
annually
Cytology alone
every 3 y
Yes $31,700/
LYG
NA – Probably
Chow et al. [39] – Yes $1,620,000/
QALY†
HPV with
cytology triage
every 3 y
HPV with
cytology triage
every 5 y
Yes $1,357,700/
QALY†
$3,891,300/
QALY†
3.1 Probably not
Chuck [40] – Yes $50,000/
QALY‡
Cytology with
cytology triage
with HPV
testing for
women older
than 30 y
with ASCUS
every 3 y
Cytology with
cytology triage
annually
No Cost saving $58,500/
QALY‡
– Probably
continued on next page
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Table 3 – continued
Study Subgroup
considered
Threshold
stated
explicitly
Threshold Optimal
strategy
Comparator Interval
longer
than
optimal
interval
simulated
Optimal
strategy
ICER
Next
efﬁcient
strategy
ICER
ICER ratio
between
optimal
and next
efﬁcient
strategy
Relevant
comparators
omitted
Coupé et al. [41] – Yes €20,000/
QALY
HPV with
cytology triage
every 7.5 y
HPV with
cytology triage
every 6 y
Yes €11,100/
QALY
€26,700/
QALY
2.4 Probably not
Coupé et al. [15] – Yes €20,000/
QALY
HPV with
cytology triage
every 10 y
Cytology with
cytology triage
every 10 y
No €6,700/
QALY
€22,300/
QALY
3.3 Probably
Diaz et al. [14] Vaccinated Yes €30,000/
QALY
Cytology with
HPV triage
every 5 y
No screening €24,400/
QALY
€97,000/
QALY
4.0 Probably
Goldhaber-Fiebert
et al. [42]
Vaccinated Yes $50,000–
$100,000/
QALY
Cytology with
HPV triage
switching to
HPV with
cytology triage
at age 35 y
every 5 y
Cytology with
HPV triage
switching to
HPV every 5 y
No $41,100/
QALY
$126,100/
QALY
3.1 Probably not
Goldie et al. [43] – Yes $50,000/
QALY
Cytology with
HPV triage
every 4 y
Cytology with
cytology triage
every 4 y
No $20,600/
QALY
$95,300/
QALY
4.6 Probably
Kim et al. [44] – No $50,000/
LYG
Cytology with
reﬂex HPV
triage every 5 y
Cytology with
cocollected
HPV triage
every 5 y
No $20,300/
LYG
$59,600/
LYG
2.9 Probably
Kim et al. [45] United
Kingdom
Yes $30,200/
LYG
HPV and cytology
combined
testing every
5 y
Cytology with
HPV triage
every 5 y
No $13,800/
LYG
$33,200/
LYG
2.4 Probably not
de Kok et al. [46] – Yes €20,000/
QALY
HPV with
cytology triage
every 6 y*
HPV with
cytology triage
every 7 y*
Yes €10,300/
QALY*
€21,130/
QALY*
2.1 Probably not
Kulasingham et al.
[47]
Canada No $50,000/
QALY‡
HPV with
cytology triage
every 3 y from
age 18 y
HPV with
cytology triage
every 3 y from
age 25 y
Yes $47,300/
QALY‡
$72,000/
QALY‡
1.5 Probably not
Legood et al. [48] – No £20,000–
30,000/
QALY
Cytology with
combined
triage of
Cytology with
combined
triage of
No £18,600
/LYG
NA – Probably
continued on next page
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cytology and
HPV and
combined
surveillance of
cytology and
HPV every 3–5
years
cytology and
HPV and
surveillance of
cytology alone
every 3–5 years
Mandelblatt et al. [30] – No $50,000/
QALY
Cytology alone
every 2 y
Cytology alone
every 3 y
Yes $29,800/
QALY
$56,400
/QALY
1.9 Probably not
Maxwell et al. [49] – Yes $50,000/
QALY
Cytology with
HPV triage
every 3 y
Cytology alone
every 3 y
No $14,300/
LYG
$65,500/
LYG
4.6 Probably
Mittendorf et al. [50] – No NA Combined
cytology and
HPV annually
HPV alone
annually
No €298/ LYG NA – Probably
Östensson et al. [51] – Yes €80,000/
LYG
HPV with HPV
triage every 5 y
No screening No €43,000/
LYG
€84,000/
LYG
2.0 Probably
Rogoza et al. [52] United States Yes $50,000–
$100,000/
QALY
Cytology with
cytology triage
annually
between ages
30 and 60 y
Cytology with
cytology triage
every 5 y
between ages
15 and 85 y
Yes $47,700/
QALY
$178,100/
QALY
3.7 Probably
van Rosmalen et al.
[8]
– Yes €20,000/
QALY
HPV with
cytology triage
every 6 y
HPV with
cytology triage
every 7 y
Yes €10,300/
QALY
€21,130/
QALY
2.1 Probably not
Sherlaw-Johnson and
Philips [53]
– No £20,000–
£30,000/
QALY
Combined
cytology and
HPV with
combined
cytology and
HPV triage
every 5 y
HPV with
cytology triage
every 5 y
No £22,600/
LYG
£37,900/
LYG
1.7 Probably not
Sroczynski et al. [26] – No €33,000/
QALY
HPV alone
every 2 y
HPV alone
every 3 y
Yes €28,400/
LYG
€93,700/
LYG
3.3 Probably not
Vijayaraghavan et al.
[55]
– No $50,000/
QALY‡
HPV alone
every 3 y
Cytology alone
every 3 y
No $11,400/
QALY‡
NA – Probably
Vijayaraghavan et al.
[54]
– No $50,000/
QALY
Combined
cytology and
HPV with
triage of HPV
genotyping
every 3 y
Combined
cytology and
HPV every 3 y
No $33,500/
QALY
NA – Probably
HPV, human papillomavirus; ICER, incremental cost-effectiveness ratio; LYG, life-year gained; NA, not available/applicable; QALY, quality-adjusted life-year; ASCUS, atypical cells of
undetermined signiﬁcance.
* Personal communication.
† New Taiwan dollar.
‡ Canadian dollars.
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Fig. 2 – A and B. Cost-effectiveness plane for unvaccinated women reinterpreted from Accetta et al. [31] with the triangles and
pentagons marking 3- and 5-year interval strategies, respectively, and panel B including hypothetical estimates for longer
intervals of 6, 7, and 8 years and the possible change in the efﬁcient frontier. HPV, human papillomavirus; QALY, quality-
adjusted life-year.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 1 3 8 – 1 1 5 11146not within the CEA-relevant range. Figure 4 graphs estimates for
combinations of cytology and HPV testing at 2- and 3-year
intervals from Mandelblatt et al. [30]. The 2-year interval strategy
is optimal because it has the highest ICER within the threshold.The inclusion of a 4-year interval comparator, represented here as
a hypothetical estimate marked with the square, would probably
increase the ICER of 3-yearly screening but not affect that
of 2-yearly screening. So although the inclusion of additional
Fig. 3 – Cost-effectiveness plane from Goldie et al. [43] showing the CEA-relevant section of the efﬁcient frontier with various
screening strategies, with dashes, triangles, and squares representing intervals of 2, 3, and 4 years, respectively, and the
inclusion of a hypothetical strategy with an interval of 5 years marked with a pentagon. HPV, human papillomavirus; QALY,
quality-adjusted life-year.
Fig. 4 – Cost-effectiveness plane from Mandelblatt et al. [30] showing efﬁcient frontier with dashes and triangles marking
screening intervals of 2 and 3 years, respectively, and the inclusion of a hypothetical strategy with an interval of 4 years
marked with a square. QALY, quality-adjusted life-year.
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 1 3 8 – 1 1 5 11148comparators with longer intervals would likely change the fron-
tier, the change is below the CEA-relevant portion and is therefore
of little signiﬁcance.
The inﬂuence of the choice of comparator strategies can be
further illustrated by showing how an analysis simulating a
large range of screening alternatives differs when restricted to
relatively intense screening strategies. The gray points and the
gray line in Figure 5 show the costs and effects estimates and
efﬁcient frontier for all strategies assessed in van Rosmalen
et al. [8]. The costs and effects estimates for the dominated
strategies were sourced through personal communication. The
estimates have been rescaled to per-woman estimates from the
original source for consistency with the other ﬁgures presented.
This analysis includes a much wider range of screening intervals
and age ranges than considered in most of the reviewed studies.
The ICERs are included at two points on the frontier to illustrate
the broad range of ratios estimated in this case. The analysis can
be constrained to higher-intensity strategies typical of many of
the studies included in this review. The black points and the
black line show the estimates and frontier for strategies with
intervals no longer than 5 years and screening age ranges that
start no later and ﬁnish no earlier than ages 25 and 60 years,
respectively.
Such a restriction omits very many of the efﬁcient strategies
from the complete analysis and ﬁnds strategies that are dominated
in the complete analysis to be efﬁcient. The optimal strategies given
the Dutch threshold of €20,000/QALY in the complete and restricted
analyses are circled. The restricted analysis would lead to the
selection of a program with eight rather than three lifetime screens
that costs approximately 2.5 times more. Finally, the only efﬁcient
strategy common to both analyses is the most costly and most
effective strategy. The restricted analysis estimates an ICER ofFig. 5 – Cost-effectiveness plane from van Rosmalen et al. [8] for
restricted set of strategies with shorter screening intervals and
strategies for a given threshold of €20,000/QALY circled in each c
analysis marked by the hollow squares. QALY, quality-adjusted€68,700/QALY for this strategy, whereas the unrestricted analysis
ﬁnds a considerably higher ICER of €122,500/QALY.Excluding Relevant Comparators from the Base Case
A secondary issue with the choice of comparators identiﬁed by
this review is the exclusion of strategies from the base case that
are simulated elsewhere in the analysis. This issue occurs in 5
of the 30 studies reviewed. Three studies featured additional
strategies in secondary analyses that were not included in the
base case [8,26,37]. Importantly, some of these additional
strategies dominate strategies found to be efﬁcient in the base
case. For example, Figure 5 shows the cost-effectiveness esti-
mates from van Rosmalen et al. [8], including two strategies
marked with the hollow squares considered in a sensitivity
analysis in which the order of cytology and HPV testing
between primary screening and triage is reversed at age
33 years.
Two other studies estimated costs and effects for a range of
screening strategies, but excluded strategies that were less
effective than the status quo when estimating ICERs, instead
using the status quo as the comparator [33,40]. Consequently, in
both studies, the ICER estimate for one strategy is underesti-
mated and the ICER estimates for some efﬁcient strategies are
omitted.
These examples of exclusions of alternative strategies from
the base case are analogous to the examples of comparator
omission identiﬁed in Table 3. Relevant strategies or comparators
are omitted from the base-case analysis, meaning that what
strategy is identiﬁed as optimal may be contingent on what
analysts chose to compare.all strategies in the original analysis shown in gray and for a
longer screening ages shown in black, with the optimal
ase and two switching strategies considered in a sensitivity
life-year.
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To date, there has been no systematic consideration of how
cervical screening CEAs have addressed the expanded range of
screening possibilities offered by HPV testing. This review adds to
the literature by appraising the choice of comparator strategies in
HPV screening CEAs with respect to the adequacy of ICER
estimates. It has shown that many of these CEAs probably
include insufﬁcient comparator strategies to reliably estimate
ICERs along the CEA-relevant portion of the efﬁcient frontier. In
particular, it is likely that many of the studies reviewed have not
included strategies with sufﬁciently long screening intervals.
The omission of relevant comparators can lead to large errors
in the ICER. The example from Goldie et al. [43] shows that a
fourfold difference in the ICER can result from the omission of a
longer interval. Such differences are not trivial and could lead to
the mistaken adoption of cost-ineffective strategies. Similarly,
the example of van Rosmalen et al. [8] shows that a restriction of
the choice set could lead to the misidentiﬁcation of an inefﬁcient
strategy as optimal and a 2.5-fold increase in screening costs.
Another problem identiﬁed in this review is that some CEAs
exclude strategies from the base case, despite being shown to be
relevant in secondary analyses. This could justiﬁably be consid-
ered a presentational issue rather than an analytical error. It
should be acknowledged, however, that such reporting creates
scope for misinterpretation and may confuse decision makers
regarding which strategies are cost-effective and which are not.
That many of the studies reviewed appear to include insufﬁ-
cient comparators is clearly a critical ﬁnding. It is however
important to acknowledge a number of important caveats. The
ﬁrst is that subjective judgment is involved when deciding
whether sufﬁcient comparators have been simulated or not.
Although the methods and evidence supporting this review’s
conclusions have been documented, much relies on inference
from previous studies regarding how the shape of the efﬁcient
frontier varies with screening intensity.
A second important caveat is that the conclusion of compa-
rator omission depends in part on the cost-effectiveness thresh-
old. The ﬁndings of this review would differ in particular cases if
the threshold was different. For example, in the case of Goldie
et al. [43] if a threshold of $100,000/QALY was used instead of the
$50,000/QALY, then the $95,300/QALY strategy would be optimal.
Because this strategy is supported by sufﬁcient comparators, this
would reverse the conclusion that Goldie et al. [43] probably
includes insufﬁcient comparators. Because very few countries
have explicit thresholds, it is often unclear what the CEA-relevant
portion of the efﬁcient frontier is. In turn, this also means that
the conclusion of comparator omission is less certain. An alter-
native perspective on this issue, however, is that if it is unclear
what threshold applies, then it is arguably more incumbent on
modelers to simulate a broad range of comparators because they
should estimate the efﬁcient frontier throughout the range of
ICER values that might include the threshold.
A third important caveat concerns how policy relevance is
deﬁned and how this determines modeling choices. This analysis
explicitly considers policy relevance from the perspective of CEA
and assumes that all technically feasible strategies are candi-
dates for simulation. What decision makers consider policy
relevant, however, may of course depend on other factors and
not all strategies may be judged feasible. Certain strategies may
be considered infeasible if they represent a large reduction in
screening intensity relative to current guidelines or what
screened populations are accustomed to, especially if the
expected health gains are less than those of current practice.
Indeed, differences in the screening status quo may help
explain the omission of longer screening intervals in manystudies. No North American study considered intervals longer
than 5 years, whereas 9 of 17 European CEAs did. US and
Canadian screening guidelines recommend cytology every 3
years [59,60], whereas the screening programs in the United
Kingdom and The Netherlands feature 5-years intervals [9]. It
seems plausible that analysts are reluctant to simulate strategies
with intervals much longer than current services.
Although alternative policy perspectives are certainly valid, it
is less clear to what extent they should determine what com-
parators can and cannot be assessed. Indeed, if there are
constraints on what policies are deemed feasible, then it seems
important that CEA should be free to assess the implied incre-
mental cost of these restrictions. For instance, even if 5 years is
the longest interval a decision maker judges feasible, it is
probably still necessary to include a 6-year interval comparator
against which to estimate its ICER. Without a 6-yearly compara-
tor, the ICER of 5-yearly screening will likely be determined
relative to no screening. Although this will probably yield a more
favorable ICER, this seems unsatisfactory because no screening
appears an even less feasible policy option than a 6-yearly
interval. Allowing comparators to be excluded according to what
is considered feasible means that ICERs may be arbitrarily
determined by policymaker’s preferences rather than incremen-
tal differences in costs and effects.
A limitation of this review is that it has primarily addressed
the omission of comparators with longer screening intervals that
can often be readily identiﬁed from kinked frontiers. The omis-
sion of other relevant comparators may not always be obvious.
For example, the results of van Rosmalen et al. [8] indicate that
shorter screening age ranges are also an important determinant
of screening intensity relevant when specifying comparator
strategies. This insight, however, could not be discerned from a
CEA that does not include shorter screening age ranges. The
same applies to the ﬁnding that strategies in which the order of
cytology and HPV testing is switched around age 30 years
perform better than do strategies without switching. These other
aspects of comparator choice that have not been addressed in
such detail here are also relevant.
The concerns raised here about the validity of ICERs based on
limited comparisons are not novel [4,61]. As has been noted in
the literature previously, however, the concern is not with the
adequacy of CEA methods in principle, but their correct applica-
tion in practice [62]. The role of comparator strategies is partic-
ularly important in the case of screening, because unlike in the
case of drug interventions in which the number of comparator
interventions is typically ﬁnite, the variety of possible screening
strategies means the choice of comparators is at the modeler’s
discretion. It is notable that few of the analyses gave a justiﬁca-
tion for the range of strategies compared, possibly indicating
that analysts are not explicitly aware of its signiﬁcance in
determining estimates. The issues raised here regarding com-
parator omission apply equally to CEAs of other interventions
with multiple possible comparators, including breast and color-
ectal screening, within which kinked frontiers can also be found
[63–65].
The observations of this review can be distilled into a simple
three-item checklist to avoid some of the problems described
above. First, check whether the efﬁcient frontier features marked
kinks rather than being gently curved because this may indicate
the omission of relevant comparators. Second, ensure that the
analysis includes sufﬁcient comparator strategies against which
to reliably estimate the ICERs of the CEA-relevant strategies;
ideally, the screening interval should be progressively increased
in annual increments so a range of ICERs is achieved that extends
from well below the cost-effectiveness threshold to well above it.
Finally, verify that all the relevant strategies simulated are
included in the base-case analysis.
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The importance of including relevant comparators has long been
recognized, both in CEA in general and in the particular context
of screening. Nevertheless, this review found that many CEAs of
HPV screening would probably beneﬁt from modeling more
screening strategies, especially those of longer intervals. Hope-
fully, by drawing attention to speciﬁc examples within the
literature, this review will refresh the attention of CEA analysts
to the need to choose comparators carefully. Similarly, this
analysis will hopefully help decision makers critically interpret
CEA results and to be aware of the implications of the choice of
comparator strategies for ICER estimates. Doing so will bring
easy-to-achieve enhancements to the reliability of cost-
effectiveness evidence, which, in turn, will support better, more
efﬁcient screening policies for cervical cancer and other diseases.Acknowledgments
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